IN BRIEF: Arm's Haas to leave AstraZeneca board amid new SoftBank role
AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Rene Haas will step down as a non-executive director on Thursday next week, the end of April, due to his increased executive duties. Haas is the chief executive officer of UK-based computer-chip designer Arm Holdings PLC and earlier this week was named to the additional role of CEO of SoftBank Group International. Japanese technology investor SoftBank Group Corp remains a major shareholder in Arm following its New York listing in 2023, retaining a 90% stake at the time.
In its announcement on Tuesday, SoftBank said Haas will coordinate semiconductor and artificial intelligence activities across its portfolio companies. Arm said the new role will be ‘limited and part-time’ and ‘is not intended to detract from his responsibilities’ at Arm. For its part, AstraZeneca on Thursday says: ‘Taking into account this additional workload, we have mutually agreed that Rene will not have enough time available to fully assume his AstraZeneca board member duties.’
Current AstraZeneca stock price: 14,402.00 pence
12-month change: up 39%
Copyright 2026 Alliance News Ltd. All Rights Reserved.